A decade of immune-checkpoint inhibitors in cancer therapy

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910836 · Cited by 3,723

Cancer immunotherapy: moving beyond current vaccines

Rosenberg, S. A., Yang, J. C.-H., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,980

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis

Wang, D. Y., Salem, J.-E., Cohen, J. V., Chandra, S., Menzer, C., Ye, F., Zhao, S., Das, S., Beckermann, K. E., Ha, L., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.3923 · Cited by 2,674

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

Seymour, L., Bogaerts, J., Perrone, A., Ford, R., Schwartz, L. H., Mandrekar, S., Lin, N. U., Litière, S., Dancey, J., Chen, A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30074-8 · Cited by 2,472

Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma

Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709030 · Cited by 2,246

Adjuvant pembrolizumab versus placebo in resected stage III melanoma

Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802357 · Cited by 1,906

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

Boutros, C., Tarhini, A. A., Routier, É., Lambotte, O., Ladurie, F. L. R., Carbonnel, F., Izzeddine, H., Marabelle, A., Champiat, S., Berdelou, A., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.58 · Cited by 1,100

Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy

Kiaie, S. H., Salehi‐Shadkami, H., Sanaei, M., Azizi, M., Barough, M. S., Nasr, M. S., & Sheibani, M. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02083-y · Cited by 83

Immune checkpoint inhibitor-associated myocarditis: a novel risk score

Power, J. R., Dolladille, C., Özbay, B., Procureur, A., Éderhy, S., Palaskas, N. L., Lehmann, L., Cautela, J., Courand, P., Hayek, S. S., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf315 · Cited by 102

3D Culture Systems for Exploring Cancer Immunology

Fitzgerald, A. A., Li, E., & Weiner, L. M. (2020) · Cancers · doi:10.3390/cancers13010056 · Cited by 85

mRNA in cancer immunotherapy: beyond a source of antigen

Hoecke, L. V., Verbeke, R., Dewitte, H., Lentacker, I., Vermaelen, K. Y., Breckpot, K., & Lint, S. V. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01329-3 · Cited by 85

Modulation of the tumor microenvironment (TME) by melatonin

Qi, M., & Najafi, M. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174365 · Cited by 82

Cellular kinetics: A clinical and computational review of CAR-T cell pharmacology

Qi, T., McGrath, K. V., Ranganathan, R., Dotti, G., & Cao, Y. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114421 · Cited by 80

Neurological complications of cancer immunotherapy

Roth, P., Winklhofer, S. F.-X., Müller, A. M. S., Dummer, R., Mair, M. J., Gramatzki, D., Rhun, É. L., Manz, M. G., Weller, M., & Preusser, M. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102189 · Cited by 80

An immune score reflecting pro- and anti-tumoural balance of tumour microenvironment has major prognostic impact and predicts immunotherapy response in solid cancers

Mezheyeuski, A., Backman, M., Mattsson, J. S. M., Martín-Bernabé, A., Larsson, C., Hrynchyk, I., Hammarström, K., Ström, S., Ekström, J., Mauchanski, S., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104452 · Cited by 85

Contextual AI models for single-cell protein biology

Li, M. M., Huang, Y., Sumathipala, M. G., Liang, M. Q., Valdeolivas, A., Ananthakrishnan, A. N., Liao, K. P., Marbach, D., & Žitnik, M. (2024) · Nature Methods · doi:10.1038/s41592-024-02341-3 · Cited by 85

Evolution of Cancer Vaccines—Challenges, Achievements, and Future Directions

Tay, B. Q., Wright, Q., Ladwa, R., Perry, C., Leggatt, G., Simpson, F., Wells, J. W., Panizza, B. J., Frazer, I. H., & Cruz, J. L. G. (2021) · Vaccines · doi:10.3390/vaccines9050535 · Cited by 76

Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy

Lee, J., Han, Y., Wang, W., Jo, H., Kim, H., Kim, S., Yang, K., Kim, S., Dhanasekaran, D. N., & Song, Y. S. (2021) · Biomolecules · doi:10.3390/biom11081107 · Cited by 83

Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells

Hiltensperger, M., & Krackhardt, A. M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1121030 · Cited by 79

Injectable cold atmospheric plasma-activated immunotherapeutic hydrogel for enhanced cancer treatment

Fang, T., Cao, X., Shen, B., Chen, Z., & Chen, G. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122189 · Cited by 76

Design and engineering of bispecific antibodies: insights and practical considerations

Madsen, A. V., Pedersen, L. E., Kristensen, P. K., & Goletz, S. (2024) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2024.1352014 · Cited by 79

Engineered tumor cell-derived vaccines against cancer: The art of combating poison with poison

Zhang, X., Cui, H., Zhang, W., Li, Z., & Gao, J. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.10.016 · Cited by 78

Microfluidic Organoid Cultures Derived from Pancreatic Cancer Biopsies for Personalized Testing of Chemotherapy and Immunotherapy

Choi, D., Gonzalez‐Suarez, A. M., Dumbravă, M., Medlyn, M. J., de Hoyos‐Vega, J. M., Cichocki, F. M., Miller, J. S., Li, D., Zhu, M., Stybayeva, G., et al. (2023) · Advanced Science · doi:10.1002/advs.202303088 · Cited by 76

Nanovaccines: An effective therapeutic approach for cancer therapy

Gurunathan, S., Pratheep, T., Wang, L., Cao, Q., & Kim, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115992 · Cited by 78

Carbonic Anhydrase IX Inhibitors as Candidates for Combination Therapy of Solid Tumors

Kalinin, S., Михайловна, М. А., Sharonova, T. V., Sharoyko, V. V., Bunev, A. S., Supuran, C. T., & Krasavin, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413405 · Cited by 78

The PCSK9 discovery, an inactive protease with varied functions in hypercholesterolemia, viral infections, and cancer

Seidah, N. G. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100130 · Cited by 78

Immunotherapies for hepatocellular carcinoma

Liu, J. K. H., Irvine, A. F., Jones, R. L., & Samson, A. (2021) · Cancer Medicine · doi:10.1002/cam4.4468 · Cited by 72

Novel epigenetic therapeutic strategies and targets in cancer

Babar, Q., Saeed, A., Tabish, T. A., Pricl, S., Townley, H. E., & Thorat, N. D. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2022.166552 · Cited by 77

Synergistic potential of immune checkpoint inhibitors and therapeutic cancer vaccines

Oladejo, M., Paulishak, W., & Wood, L. M. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.12.003 · Cited by 75

First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)

Postel-Vinay, S. C., Lam, V. K. L., Ros, W., Bauer, T. M., Hansen, A. R., Cho, D. C., Hodi, F. S., Schellens, J. H. M., Litton, J. K., Aspeslagh, S., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005301 · Cited by 73

Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study

Espi, M., Teuma, C., Novel-Catin, E., Maillet, D., Souquet, P. J., Dalle, S., Koppe, L., & Fouque, D. P. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.01.005 · Cited by 72

Laser ablation: Heating up the anti-tumor response in the intracranial compartment

Lerner, E., Edwards, R. M., Wilkinson, D. S., & Fecci, P. E. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114311 · Cited by 72

Targeting novel regulated cell death: Ferroptosis, pyroptosis and necroptosis in anti‐PD ‐1/ PD‐L1 cancer immunotherapy

Yu, L., Huang, K., Liao, Y., Wang, L., Sethi, G., & Ma, Z. (2024) · Cell Proliferation · doi:10.1111/cpr.13644 · Cited by 71

Advanced Polymeric Nanoparticles for Cancer Immunotherapy: Materials Engineering, Immunotherapeutic Mechanism and Clinical Translation

Jia, W., Wu, Y., Xie, Y., Yu, M., & Chen, Y. (2025) · Advanced Materials · doi:10.1002/adma.202413603 · Cited by 77

Evaluation of the TCR Repertoire as a Predictive and Prognostic Biomarker in Cancer: Diversity or Clonality?

Aran, A., Garrigós, L., Curigliano, G., Cortés, J., & Martı́, M. (2022) · Cancers · doi:10.3390/cancers14071771 · Cited by 72

Efficacy, Safety, and Challenges of CAR T-Cells in the Treatment of Solid Tumors

Chen, Q., Lu, L., & Ma, W. (2022) · Cancers · doi:10.3390/cancers14235983 · Cited by 73

Injectable hydrogels for personalized cancer immunotherapies

Mohaghegh, N., Ahari, A. F., Zehtabi, F., Buttles, C., Davani, S., Hoang, H., Tseng, K., Zamanian, B. B., Khosravi, S., Daniali, A., et al. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.10.002 · Cited by 72

Immune Checkpoint Inhibitor Use During Pregnancy and Outcomes in Pregnant Individuals and Newborns

Gougis, P., Hamy, A., Jochum, F., Bihan, K., Carbonnel, M., Salem, J., Dumas, É., Kabirian, R., Grandal, B., Barraud, S., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.5625 · Cited by 69

Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer

Daniello, L., Elshiaty, M., Bozorgmehr, F., Kuon, J., Kazdal, D. N., Schindler, H., Shah, R., Volckmar, A., Lusky, F., Diekmann, L., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.703893 · Cited by 70

Human adipose-derived mesenchymal stem cells prevent type 1 diabetes induced by immune checkpoint blockade

Kawada-Horitani, E., Kita, S., Okita, T., Nakamura, Y., Nishida, H., Honma, Y., Fukuda, S., Tsugawa-Shimizu, Y., Kozawa, J., Sakaue, T., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05708-3 · Cited by 69

Engineering tumor-specific gene nanomedicine to recruit and activate T cells for enhanced immunotherapy

Wang, Y., Zhou, S., Wang, Y., Lu, Z.-D., Zhang, Y., Xu, C., & Wang, J. (2023) · Nature Communications · doi:10.1038/s41467-023-37656-w · Cited by 67

Lipid‐based nanoparticles as drug delivery systems for cancer immunotherapy

Hao, Y., Ji, Z., Zhou, H., Wu, D., Gu, Z., Wang, D., & ten Dijke, P. (2023) · MedComm · doi:10.1002/mco2.339 · Cited by 71

Injectable Hydrogels as Local Depots at Tumor Sites for Antitumor Immunotherapy and Immune‐Based Combination Therapy

Ma, H., He, C., & Chen, X. (2021) · Macromolecular Bioscience · doi:10.1002/mabi.202100039 · Cited by 64

Emerging immune checkpoints in the tumor microenvironment: Implications for cancer immunotherapy

Wei, G., Zhang, H., Zhao, H., Wang, J., Wu, N., Li, L., Wu, J., & Zhang, D. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.04.021 · Cited by 66

Combining Photothermal‐Photodynamic Therapy Mediated by Nanomaterials with Immune Checkpoint Blockade for Metastatic Cancer Treatment and Creation of Immune Memory

Lima‐Sousa, R., Melo, B. L., Alves, C. G., Moreira, A. F., Mendonça, A., Correia, I. J., & de Melo‐Diogo, D. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202010777 · Cited by 65

Epigenetic regulation and T-cell responses in endometriosis – something other than autoimmunity

Szukiewicz, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.943839 · Cited by 65

Neutrophil to Lymphocyte ratio as a predictor for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis

Zhang, W., Tan, Y., Li, Y., & Liu, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1234142 · Cited by 64

Cancer immunomodulation using bispecific aptamers

Thomas, B. J., Porciani, D., & Burke, D. H. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.01.008 · Cited by 62

PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer

Liu, P., Chen, J., Zhao, L., Hollebecque, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2093518 · Cited by 64

PSMA Theranostics: Current Landscape and Future Outlook

Zhang, H., Koumna, S., Pouliot, F., Beauregard, J., & Kolinsky, M. P. (2021) · Cancers · doi:10.3390/cancers13164023 · Cited by 66

Trial watch: intratumoral immunotherapy

Humeau, J., Naour, J. L., Galluzzi, L., Kroemer, G., & Pol, J. G. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1984677 · Cited by 62

Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma

Mørk, S. K., Kadivar, M., Bol, K. F., Draghi, A., Westergaard, M. C. W., Skadborg, S. K., Overgaard, N. H., Sørensen, A. B., Rasmussen, I. S., Andreasen, L. V., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2021.2023255 · Cited by 62

NIR-II laser-mediated photo-Fenton-like reaction via plasmonic Cu9S8 for immunotherapy enhancement

An, L., Wang, C., Tian, Q., Tao, C., Xue, F., Yang, S., Zhou, X., Chen, X. S., & Huang, G. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101397 · Cited by 62

Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites

Conway, J. W., Rawson, R. V., Lo, S., Ahmed, T., Vergara, I. A., Gide, T. N., Attrill, G. H., Carlino, M. S., Saw, R. P. M., Thompson, J. F., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004884 · Cited by 69

Bioengineered Platelets Combining Chemotherapy and Immunotherapy for Postsurgical Melanoma Treatment: Internal Core-Loaded Doxorubicin and External Surface-Anchored Anti-PD-L1 Antibody Backpacks

Qi, L., Ye, H., Wang, K., Zhao, J., Wang, H., Song, J., Fan, X., Lu, Y., Cao, L., Wan, B., et al. (2022) · Nano Letters · doi:10.1021/acs.nanolett.2c00907 · Cited by 61

Immunotherapy in Glioblastoma: Current Approaches and Future Perspectives

Sener, U. T., Ruff, M. W., & Campian, J. L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137046 · Cited by 61

The Impact of Gut Microbiota-Derived Metabolites on the Tumor Immune Microenvironment

Luu, M., Schütz, B., Lauth, M., & Visekruna, A. (2023) · Cancers · doi:10.3390/cancers15051588 · Cited by 65

Receptor Elimination by E3 Ubiquitin Ligase Recruitment (REULR): A Targeted Protein Degradation Toolbox

Siepe, D. H., Picton, L. K., & García, K. C. (2023) · ACS Synthetic Biology · doi:10.1021/acssynbio.2c00587 · Cited by 62

mRNA-LNP vaccination-based immunotherapy augments CD8+ T cell responses against HPV-positive oropharyngeal cancer

Qiu, K., Duan, X., Mao, M., Song, Y., Rao, Y., Cheng, D., Feng, L., Shao, X., Jiang, C., Huang, H., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00733-8 · Cited by 63

Sialylated glycoproteins suppress immune cell killing by binding to Siglec-7 and Siglec-9 in prostate cancer

Wen, R. M., Stark, J. C., Marti, G. E., Fan, Z., Lyu, A., Garcia-Marques, F. J., Zhang, X., Riley, N. M., Totten, S. M., Bermudez, A., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci180282 · Cited by 61

Revised European Society of Endocrinology Clinical Practice Guideline for the management of aggressive pituitary tumours and pituitary carcinomas

Raverot, G., Burman, P., Abreu, A. P., Heaney, A. P., van Hulsteijn, L. T., Lin, A. L., Marcus, H. J., McCormack, A. I., Minniti, G., Petersenn, S., et al. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf100 · Cited by 74

Trial watch: an update of clinical advances in photodynamic therapy and its immunoadjuvant properties for cancer treatment

Penetra, M., Arnaut, L. G., & Gomes-da-Silva, L. C. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2226535 · Cited by 61

Ferritin‐Based Nanocomposite Hydrogel Promotes Tumor Penetration and Enhances Cancer Chemoimmunotherapy

Liu, R., Liang, Q. Y., Luo, J., Li, Y., Zhang, X., Fan, K., & Du, J. (2023) · Advanced Science · doi:10.1002/advs.202305217 · Cited by 60

Kickstarting Immunity in Cold Tumours: Localised Tumour Therapy Combinations With Immune Checkpoint Blockade

Appleton, E. S., Hassan, J., Hak, C. C. W., Sivamanoharan, N., Wilkins, A. C., Samson, A., Ono, M., Harrington, K. J., Melcher, A. A., & Wennerberg, E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.754436 · Cited by 63

Dual-driven nanomotors enable tumor penetration and hypoxia alleviation for calcium overload-photo-immunotherapy against colorectal cancer

Wu, J., Yi, S., Cao, Y., Zu, M., Li, B., Yang, W. J., Shahbazi, M., Wan, Y., Reis, R. L., Kundu, S. C., et al. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122332 · Cited by 59

Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors

Ruf, T., Kramer, R., Forschner, A., Leiter, U., Meier, F. E., Reinhardt, L., Dücker, P., Ertl, C., Tomsitz, D., Tietze, J. K., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114028 · Cited by 59

Engineering innate immune cells for cancer immunotherapy

Tarannum, M., Ding, X., Barisa, M., Hu, S., Anderson, J., Romee, R., & Zhang, J. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02629-5 · Cited by 64

A crossroad between placental and tumor biology: What have we learnt?

Lala, P. K., Nandi, P., Hadi, A., & Halari, C. D. (2021) · Placenta · doi:10.1016/j.placenta.2021.03.003 · Cited by 61

Locally Injectable Hydrogels for Tumor Immunotherapy

Zhang, X., Guo, X., Wu, Y. F., & Gao, J. (2021) · Gels · doi:10.3390/gels7040224 · Cited by 61

Inhibition of integrin αvβ6 sparks T-cell antitumor response and enhances immune checkpoint blockade therapy in colorectal cancer

Busenhart, P., Montalban‐Arques, A., Katkeviciutė, E., Morsy, Y., Passen, C. V., Hering, L., Atrott, K., Lang, S., Garzon, J. F. G., Naschberger, E., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003465 · Cited by 59

Towards a better understanding of human iNKT cell subpopulations for improved clinical outcomes

Look, A., Burns, D., Tews, I., Roghanian, A., & Mansour, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1176724 · Cited by 58

Cancer Biomarkers and Precision Oncology: A Review of Recent Trends and Innovations

AlDoughaim, M., Alsuhebany, N., Alzahrani, M., Alqahtani, T., Alghamdi, S. S., Badreldin, H. A., & Alshaykh, H. A. (2024) · Clinical Medicine Insights Oncology · doi:10.1177/11795549241298541 · Cited by 68

Carfilzomib modulates tumor microenvironment to potentiate immune checkpoint therapy for cancer

Zhou, Q., Liang, J., Yang, T., Liu, J., Li, B., Li, Y., Fan, Z., Wang, W., Chen, W., Yuan, S., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202114502 · Cited by 57

Association of Immune Checkpoint Inhibitors With Neurologic Adverse Events

Farooq, M. Z., Aqeel, S. B., Lingamaneni, P., Pichardo, R., Jawed, A., Khalid, S., Banskota, S. U., Fu, P., & Mangla, A. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.7722 · Cited by 63

Synthetic enforcement of STING signaling in cancer cells appropriates the immune microenvironment for checkpoint inhibitor therapy

Vornholz, L., Isay, S. E., Kurgyis, Z., Strobl, D. C., Loll, P., Mosa, M. H., Luecken, M. D., Sterr, M., Lickert, H., Winter, C., et al. (2023) · Science Advances · doi:10.1126/sciadv.add8564 · Cited by 60

Multimodal synergistic ferroptosis cancer therapy

Singh, N., Kim, D., Min, S., Kim, E., Kim, S., Zhang, Y. S., Kang, H., & Kim, J. S. (2024) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2024.216236 · Cited by 57

Mannosylated STING Agonist Drugamers for Dendritic Cell-Mediated Cancer Immunotherapy

Nguyen, D. C., Song, K., Jokonya, S., Yazdani, O., Sellers, D. L., Wang, Y., Zakaria, A., Pun, S. H., & Stayton, P. S. (2024) · ACS Central Science · doi:10.1021/acscentsci.3c01310 · Cited by 56

Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics

Saini, K. S., Punie, K., Twelves, C. J., Bortini, S., de Azambuja, E., Anderson, S., Criscitiello, C., Awada, A. H., & Loi, S. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1936494 · Cited by 58

Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives

Rebuzzi, S. E., Rescigno, P., Catalano, F., Mollica, V., Vogl, U. M., Marandino, L., Massari, F., Mestre, R. P., Zanardi, E., Signori, A., et al. (2022) · Cancers · doi:10.3390/cancers14051245 · Cited by 56

Targeting Transcription Factor YY1 for Cancer Treatment: Current Strategies and Future Directions

Hosea, R., Hillary, S., Wu, S., & Kasim, V. (2023) · Cancers · doi:10.3390/cancers15133506 · Cited by 57

Immune-Checkpoint Inhibitors-Induced Type 1 Diabetes Mellitus: From Its Molecular Mechanisms to Clinical Practice

Cho, Y. K., & Jung, C. H. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0072 · Cited by 56

Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer

Federico, A. D., Alden, S. L., Smithy, J. W., Ricciuti, B., Alessi, J. V., Wang, X., Pecci, F., Lamberti, G., Gandhi, M. M., Vaz, V. R., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.06.014 · Cited by 57

Peripheral nervous system adverse events associated with immune checkpoint inhibitors

Rossi, S., Gelsomino, F., Rinaldi, R., Muccioli, L., Comito, F., Federico, A. D., Giglio, A. D., Lamberti, G., Andrini, E., Mollica, V., et al. (2023) · Journal of Neurology · doi:10.1007/s00415-023-11625-1 · Cited by 54

Using Combination therapy to overcome diverse challenges of Immune Checkpoint Inhibitors treatment

Birnboim-Perach, R., & Benhar, I. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.93697 · Cited by 58

IL-17–induced HIF1α drives resistance to anti–PD-L1 via fibroblast-mediated immune exclusion

Chen, X., Zhao, J., Herjan, T., Hong, L., Liao, Y., Liu, C., Vasu, K., Wang, H., Thompson, A., Fox, P. L., et al. (2022) · Journal of Experimental Medicine · doi:10.1084/jem.20210693 · Cited by 53

Natural Compounds of Marine Origin as Inducers of Immunogenic Cell Death (ICD): Potential Role for Cancer Interception and Therapy

Sansone, C., Bruno, A., Piscitelli, C., Baci, D., Fontana, A., Brunet, C., Noonan, D. M., & Albini, A. (2021) · Cells · doi:10.3390/cells10020231 · Cited by 55

Technology meets TILs: Deciphering T cell function in the -omics era

Hudson, W. H., & Wieland, A. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.09.011 · Cited by 55

The Impact of Systemic Oncological Treatments on the Fertility of Adolescents and Young Adults—A Systematic Review

Himpe, J., Lammerant, S., Bergh, L. V. D., Lapeire, L., & Roo, C. D. (2023) · Life · doi:10.3390/life13051209 · Cited by 66

A review of lactate-lactylation in malignancy: its potential in immunotherapy

Zha, J., Zhang, J., Lu, J., Zhang, G., Hua, M., Guo, W., Yang, J., & Fan, G. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1384948 · Cited by 57

How cancer cells remodel lipid metabolism: strategies targeting transcription factors

Jeong, D., Lee, S., & Chun, Y. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01593-8 · Cited by 57

Protein S-palmitoylation modification: implications in tumor and tumor immune microenvironment

Chen, Y., Li, Y., & Wu, L. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1337478 · Cited by 53

The crosstalk between immune cells and tumor pyroptosis: advancing cancer immunotherapy strategies

Hu, M., Deng, F., Song, X., Zhao, H., & Yan, F. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03115-7 · Cited by 57

From big data and experimental models to clinical trials: Iterative strategies in microbiome research

Turjeman, S., Rozera, T., Elinav, E., Ianiro, G., & Koren, O. (2025) · Cell · doi:10.1016/j.cell.2025.01.038 · Cited by 58

SynNotch CAR-T cell, when synthetic biology and immunology meet again

Shirzadian, M., Moori, S., Rabbani, R., & Rahbarizadeh, F. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1545270 · Cited by 55

Immunotherapy for SMARCB1-Deficient Sarcomas: Current Evidence and Future Developments

Ngo, C., & Postel-Vinay, S. C. (2022) · Biomedicines · doi:10.3390/biomedicines10030650 · Cited by 54

Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab

Hsu, C., Rimassa, L., Sun, H., Vogel, A., & Kaseb, A. O. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211031141 · Cited by 51

Renin–angiotensin–aldosterone system inhibitors and survival in patients with hypertension treated with immune checkpoint inhibitors

Drobni, Z. D., Michielin, O. A., Quinaglia, T., Zlotoff, D. A., Zubiri, L., Gilman, H. K., Sama, S., Merkely, B. P., Müller, V., Sullivan, R. J., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2021.12.024 · Cited by 49

Escherichia coli Mimetic Gold Nanorod-Mediated Photo- and Immunotherapy for Treating Cancer and Its Metastasis

Hwang, J., An, E., Kim, S., Zhang, W., & Jin, J. (2022) · ACS Nano · doi:10.1021/acsnano.2c03379 · Cited by 52

Current progress of nanomedicine for prostate cancer diagnosis and treatment

Zhao, J., Zhang, C., Wang, W., Li, C., Mu, X., & Hu, K. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113714 · Cited by 57

Severe vs Nonsevere Immune Checkpoint Inhibitor-Induced Myocarditis

Zadok, O. I. B., Levi, A., Divakaran, S., & Nohria, A. (2023) · JACC CardioOncology · doi:10.1016/j.jaccao.2023.09.004 · Cited by 54

Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: An international retrospective cohort study

Moeckli, B., Wassmer, C., Hajji, S. E., Kumar, R., Ribeiro, J. R., Tabrizian, P., Feng, H., Schnickel, G. T., Kulkarni, A. V., Allaire, M., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000001289 · Cited by 51

The paradox of immune checkpoint inhibition re-activating tuberculosis

Ahmed, M. I. M., Tezera, L. B., Elkington, P. T., & Leslie, A. J. (2022) · European Respiratory Journal · doi:10.1183/13993003.02512-2021 · Cited by 53

Molecular mechanisms of action of metformin: latest advances and therapeutic implications

Zhu, H., Jia, Z., Li, Y. R., & Danelisen, I. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01051-y · Cited by 59

Malignant Superior Vena Cava Syndrome: A Scoping Review

Wright, K., Digby, G. C., Gyawali, B., Jad, R., Ménard, A., de Moraes, F. Y., & Wijeratne, D. T. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.04.019 · Cited by 50

Bone metastases diminish extraosseous response to checkpoint blockade immunotherapy through osteopontin-producing osteoclasts

Cheng, J., Jin, Z., Su, C., Jiang, T., Zheng, X., Guo, J., Li, X., Chu, H., Jia, J., Zhou, Q., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.03.036 · Cited by 55

The solid tumor microenvironment—Breaking the barrier for T cells

Şimşek, H., & Klotzsch, E. (2022) · BioEssays · doi:10.1002/bies.202100285 · Cited by 50

PCSK9 in metabolism and diseases

Ajoolabady, A., Pratico, D., Mazidi, M., Davies, I. G., Lip, G. Y. H., Seidah, N., Libby, P., Kroemer, G., & Ren, J. (2025) · Metabolism · doi:10.1016/j.metabol.2024.156064 · Cited by 49

["Immune checkpoint inhibitors in oncology"].

Daëron, M., & Vivier, É. (2021) · PubMed

Meditating on Cancer Management at the Time of Immunotherapy

Lopci, E. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11113025

Redefining success: predicting checkpoint inhibitor toxicity to improve patient outcomes

Weidhaas, J. B. (2022) · Immuno Oncology Insights · doi:10.18609/ioi.2022.030

Immunotherapy for cancer

Lee, A. J. X. (2022) · Medicine · doi:10.1016/j.mpmed.2022.10.007 · Cited by 3

Immuno-oncology: A changing paradigm in cancer therapy

Abdel-Rahman, O. M. (2016) · Advances in Modern Oncology Research · doi:10.18282/amor.v2.i6.187 · Cited by 1